Adlai Nortye Group Ltd. ANL

Company Overview

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cancer therapies, primarily in the oncology and immuno-oncology sectors. The company’s core activities center on developing novel biologics and small-molecule drugs intended to address unmet medical needs in solid tumors and hematologic malignancies. Its primary revenue drivers are research and development collaborations, milestone-based payments, and, to a limited extent, government grants, as the company does not yet generate material product sales.

Founded in 2014, Adlai Nortye has evolved from an early-stage research organization into a publicly listed biotechnology company on the Hong Kong Stock Exchange (stock code: 9939). The company is recognized for its translational research capabilities and its strategy of combining internal drug discovery with external partnerships. Its positioning emphasizes differentiated mechanisms of action and combination therapies, particularly those integrating immunotherapy with targeted approaches.